


REMARKS

Applicant requests entry of the Amendment as a matter of grace under the guidelines 37 CFR 1.312, amendment after the mailing of the notice of allowance. It is filed before the date the issue fee is paid and it merely corrects a formal matter in the specification without changing the scope thereof. It does not change the scope of the claims. Upon review of the Examiner's Amendment in the Notice of Allowance mailed on January 8, 2008, Applicant found no errors and makes no objections to the Examiner's Amendments or Allowed Claims; however, Applicant seeks the amendments above in order to correct two letter errors found in the top line sequence in Table 1, on page 32. There is a single letter error at amino acid position 115 and a single letter error at amino acid position 156, these are both in roughly line 20 on page 32. At residue position 115 the residue letter should be indicated by the letter "K" (lysine) and at position 156 the residue should be indicated by the letter "F" (phenylalanine). These changes will make the sequence in Table 1, the natural or wild type INF-beta-1a, identical to the sequence in Figure 10, Met-18-Arg-183 which is described as the natural INF-beta-1a, and identical to Seq. 41, also wild type INF-beta-1a, examined and allowed here and as discussed in the Office Actions and Replies previously filed in this application.

The amendment does not introduce any new matter to the specification or change the scope or examination of the claims. This amendment simply provides for the correction of a formal matter in the specification. It is believed needed for the proper disclosure of the application and does not require any additional work on the part of the Office.

Respectfully submitted,

Date: January 15, 2008


Thomas A. Wootton
Reg. No. 35,004

Miller, Canfield, Paddock and Stone, P.L.C.
444 West Michigan Avenue
Kalamazoo, MI 49007
Telephone: (269) 381-7030
Facsimile: (269) 383-5828